Business Wire

Inaugural Virtual Edition of LiveWorx Digital Transformation Event Draws Thousands

1.7.2020 23:00:00 EEST | Business Wire | Press release

Share

For the first time in the event’s decade-long history, the annual LiveWorx® digital transformation event took place online, uniting tens of thousands of industry leaders across the world. Chaired by presenting sponsor, PTC (NASDAQ: PTC), the one-day event featured more than 120 sessions spanning topics ranging from Augmented Reality (AR), Artificial Intelligence (AI), 5G, Robotics, Software as a Service (SaaS), Industrial Internet of Things (IIoT), Product Lifecycle Management (PLM), and Computer-Aided Design (CAD), and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200701005892/en/

“This year’s virtual event brought to life the magic, excitement, and drive for transformative change that we all experience at the annual in-person version,” said Jim Heppelmann, President and CEO, PTC. “I was particularly pleased to see the force of change magnified inside and outside of this year’s event. For the global society, 2020 has been a year of challenge and growth. I look forward to seeing how this year’s energy and drive will be matched in next year’s event.”

Energizing Change

In support of movements and causes that shape the world in which the technology community operates, the LiveWorx event recognized four charities as beneficiaries for donations stemming from attendee actions throughout the event. For each attendee who entered the virtual Networking Lounge, shared their experience on social media using #LiveWorx, or completed an online scavenger hunt, approximately $1 per action was donated to charities including WWF - World Wildlife Fund, International Rescue Committee, Save the Children, and Black Girls CODE. Following the event’s final keynote session, all donations were matched by presenting sponsor, PTC.

“Bringing to life the Black Girls CODE story during this year’s LiveWorx event enabled us to raise awareness of our mission across the globe, and reinforce why we need to confront this crisis today to ensure a brighter and more inclusive tomorrow,” said Kimberly Bryant, Founder and CEO, Black Girls CODE. “While there is still a lot of work to do, I am proud to have had the opportunity to share this message, and will continue to champion inclusion for all of the women entering the STEM community.”

As part of its mission to foster inclusion across the technology industry, LiveWorx continuously endeavors to reflect more gender, racial, and geographic diversity in STEM fields represented at the event. At this year’s event, 21% of presenters identified as female or non-binary, 27% of presenters were Black, Indigenous, and People of Color (BIPOC), and 23% of presenters resided outside the United States.

Thriving in the ‘New Normal’

Over the course of the one-day event, attendees heard from technology experts across the community, including the following keynote headliners:

To replay LiveWorx keynotes, track spotlights, and more, access the LiveWorx 2020 Content Archive. Event replays will be available through Spring 2021.

Major Product Announcements Put Industrial Enterprise Technology at Precipice of Future

Coinciding with the momentum and excitement surrounding LiveWorx 20, PTC shared key product releases from its ThingWorx® IIoT Platform, and Windchill® PLM Software offerings; recent advancements following November’s acquisition of the Onshape® SaaS technology; and the launch of the new Factory Insights as a Service product in collaboration with sponsors Rockwell Automation and Microsoft.

Alongside this year’s Title Sponsor, Analog Devices, 11 companies supported LiveWorx 20 including Pinnacle Sponsors Ansys, AT&T Business, Ericsson, EY, and Transition Technologies; and Premier Sponsors Archer Grey, Deloitte, EPLAN, Hewlett Packard Enterprise, and Kalypso.

About PTC (NASDAQ: PTC)

PTC enables global manufacturers to realize double-digit impact with software solutions that enable them to accelerate product and service innovation, improve operational efficiency, and increase workforce productivity. In combination with an extensive partner network, PTC provides customers flexibility in how its technology can be deployed to drive digital transformation – on premises, in the cloud, or via its pure SaaS platform. At PTC, we don’t just imagine a better world, we enable it.

PTC.com @PTC Blogs

PTC, LiveWorx, ThingWorx, Windchill, Onshape, and the PTC logo are trademarks or registered trademarks of PTC Inc. and/or its subsidiaries in the United States and other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PTC
Corporate Communications
Greg Payne
gpayne@ptc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye